BACKGROUND This study was designed to estimate economic burden of lung cancer in Turkey from payer perspective based on expert panel opinion on practice patterns in clinical practice. METHODS In this cost of illness study, direct medical cost was calculated based on cost items related to outpatient visits, laboratory and radiological tests, hospitalizations/interventions, drug treatment, adverse events and metastasis. Indirect cost was calculated based on lost productivity due to early retirement, morbidity and premature death resulting from the illness, the value of lost productivity due to time spent by family caregivers and cost of formal caregivers. RESULTS Cost analysis revealed the total per patient annual direct medical cost for small cell lung cancer to be €8772), for non-small-cell lung cancer to be €10,167. Total annual direct medical cost was €497.9 million, total annual indirect medical cost was €1.1 billion and total economic burden of lung cancer was €1.6 billion. Hospitalization/interventions (41%) and indirect costs (68.6%) were the major cost drivers for total direct costs and the overall economic burden of lung cancer, respectively. CONCLUSIONS Our findings indicate per patient direct medical costs of small cell lung cancer and non-small-cell lung cancer to be substantial and comparable, indicating the substantial economic burden of lung cancer in terms of both direct and indirect costs. Our findings indicate that hospitalization/interventions cost item and indirect costs were the major cost drivers for total direct costs and the overall economic burden of lung cancer, respectively. Our findings emphasize the potential role of improved cancer prevention and early diagnosis strategies, by enabling cost savings related to drug treatment and metastasis management cost items, in sustainability of cancer treatments.

中文翻译：

---

土耳其肺癌的经济负担：从付款人的角度进行的疾病成本研究。

背景 本研究旨在根据专家小组对临床实践实践模式的意见，从付款人的角度评估土耳其肺癌的经济负担。方法 在这项疾病成本研究中，直接医疗成本是根据与门诊、实验室和放射检查、住院/干预、药物治疗、不良事件和转移相关的成本项目计算的。间接成本的计算基于因疾病导致的提前退休、发病和过早死亡而导致的生产力损失、因家庭照顾者花费的时间而导致的生产力损失价值以及正式照顾者的成本。结果 成本分析显示，小细胞肺癌每位患者的年度直接医疗总成本为 8772 欧元，非小细胞肺癌为 10,167 欧元。年度直接医疗总费用为4.979亿欧元，年度间接医疗总费用为11亿欧元，肺癌总经济负担为16亿欧元。住院/干预（41%）和间接成本（68.6%）分别是肺癌总直接成本和整体经济负担的主要成本驱动因素。结论 我们的研究结果表明，小细胞肺癌和非小细胞肺癌的每位患者的直接医疗费用是可观的且具有可比性，表明肺癌在直接和间接费用方面的巨大经济负担。我们的研究结果表明，住院/干预成本项目和间接成本分别是肺癌总直接成本和整体经济负担的主要成本驱动因素。